ProQR Therapeutics N.V. Ordinary Shares (PRQR)

FairStock Score: 37/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

As a Buffett/Graham-style investor, I look first for durable economics and a margin of safety. ProQR is a clinical-stage biotech with an RNA editing platform and candidates AX-0810 and AX-2402, so value rests on science and regulatory outcomes, not steady cash generation. In the second quarter of 2026, revenue was $8.8M and net income was -$8.7M. The company is unprofitable: FairStock calculations at the 2026-10-13 close show a P/E of -3.22, P/B of 1.76, ROE of -57.40%, and ROCE of -19.76%. Free cash flow is -$50.2M, a -28.9% FCF yield, and the Altman Z-score is -2.55, which points to financial distress. Debt-to-equity of 0.19 is modest, but negative cash flow is the real issue. The Piotroski F-score is 4/9, and FairStock's Score is 37/100. Growth is also poor: the provided growth figures show revenue down 55.01% and profit down 32.78%, though period labels are not given. A moat is hard to identify; pipeline intellectual property may have option value, but there are no profits to protect. The Lynch category is none, because there are only 0 years of filed results and 3 are needed. P/B near 1.76 might attract a Graham-style asset buyer, but book value can be consumed by R&D losses. This is a binary clinical story, not a predictable compounder. I would want evidence of trial success, partnership validation, and slowing cash burn before calling the price a bargain.

In plain English: ProQR Therapeutics is a healthcare company working on experimental RNA medicines for genetic diseases. It is losing money, using cash, and its revenue and profit have been shrinking, so the business looks financially weak. At $1.48 on 2026-10-13, the price seems to depend on hopes for its drug pipeline rather than current numbers, so it does not look clearly cheap.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer